Although anti-TNFα therapies offer a powerful way to manage the progression and treatment of IBD, they are expensive, ineffective in more than 50% of patients, and increase the risk of infections, liver problems, arthritis, and lymphoma [3,5]. This evidence concerns the gene TNF and inflammatory bowel disease.